company background image
CASI

CASI Pharmaceuticals NasdaqCM:CASI Stock Report

Last Price

US$1.97

Market Cap

US$26.8m

7D

1.0%

1Y

-77.5%

Updated

01 Dec, 2022

Data

Company Financials +
CASI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CASI Stock Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally.

CASI Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CASI Pharmaceuticals
Historical stock prices
Current Share PriceUS$1.97
52 Week HighUS$10.30
52 Week LowUS$1.81
Beta0.42
1 Month Change-2.48%
3 Month Change-47.75%
1 Year Change-77.46%
3 Year Change-93.82%
5 Year Change-93.99%
Change since IPO-99.89%

Recent News & Updates

Casi to sell stake in Juventas to Jiadao Gongcheng for ~RMB240.87M

Sep 23

Recent updates

Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

May 26
Is CASI Pharmaceuticals (NASDAQ:CASI) In A Good Position To Deliver On Growth Plans?

Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Aug 14
Upgrade: Analysts Just Made A Captivating Increase To Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Forecasts

Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

May 25
Does CASI Pharmaceuticals (NASDAQ:CASI) Have A Healthy Balance Sheet?

Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Mar 16
Did CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Buy Up More Shares?

Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

Feb 18
Companies Like CASI Pharmaceuticals (NASDAQ:CASI) Are In A Position To Invest In Growth

How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Jan 23
How Much Of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Do Insiders Own?

Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

Dec 28
Is CASI Pharmaceuticals' (NASDAQ:CASI) 205% Share Price Increase Well Justified?

Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%

Dec 02
Growth Investors: Industry Analysts Just Upgraded Their CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Revenue Forecasts By 4.3%

The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares

Nov 27
The Chairman & CEO of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Wei-Wu He, Just Bought 4.7% More Shares

Shareholder Returns

CASIUS BiotechsUS Market
7D1.0%2.7%1.4%
1Y-77.5%-10.3%-16.1%

Return vs Industry: CASI underperformed the US Biotechs industry which returned -10.2% over the past year.

Return vs Market: CASI underperformed the US Market which returned -14.8% over the past year.

Price Volatility

Is CASI's price volatile compared to industry and market?
CASI volatility
CASI Average Weekly Movement10.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: CASI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CASI's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1991176Wei-Wu Hehttps://www.casipharmaceuticals.com

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company’s product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome.

CASI Pharmaceuticals, Inc. Fundamentals Summary

How do CASI Pharmaceuticals's earnings and revenue compare to its market cap?
CASI fundamental statistics
Market CapUS$26.80m
Earnings (TTM)-US$27.08m
Revenue (TTM)US$37.01m

0.7x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CASI income statement (TTM)
RevenueUS$37.01m
Cost of RevenueUS$15.36m
Gross ProfitUS$21.65m
Other ExpensesUS$48.73m
Earnings-US$27.08m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.99
Gross Margin58.51%
Net Profit Margin-73.17%
Debt/Equity Ratio3.6%

How did CASI perform over the long term?

See historical performance and comparison